Abstract
Menkes disease (MD; McKusick 309400) is an X-linked neurodegenerative disorder secondary to extrahepatic copper accumulation, caused by mutations of the gene encoding for the intracellular copper transporter ATPase alpha polypeptide (ATP7A). The clinical picture is characterized by severe psychomotor retardation, seizures, skin hypopigmentation and abnormal hair. Biochemically, MD patients have reduced serum levels of copper and ceruloplasmin. In some cases, early supplementation with parenteral copper histidinate reduced seizure activity and improved muscle tone and motor activity (Kreuder et al 1993). Some of the clinical findings of MD have been proposed to be secondary to reduced activities of copper-dependent enzymes (i.e. cytochrome-c-oxidase, lysyl oxidase and dopamine β-hydroxylase) (Kaler 1994). To study oxidative status and effects of copper histidinate therapy, we serially evaluated urinary organic acids in MD patients. We also evaluated respiratory chain enzymes activities in muscle and/or fibroblasts.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.